The proprietary CD technology is engineered with highly reproducible microfluidic structures which integrate 15 nL flow-through affinity columns and high precision sample volume definition chambers that ensures reproducible sample and reagent additions to the affinity columns. The affinity columns are filled with solid or porous streptavidin-coated beads for capture of biotinylated binding ligands. Detection is performed with a suitable fluorescence labelled detection reagent.
Sample and reagent additions are carefully controlled in the Gyrolab instrument by spinning the CD according to a method defined assay design protocol. The flow-through affinity micro-column format and short contact times eliminate incubations and minimizes matrix interference. The result is cost effective production of highly reproducible data over broad dynamic ranges.concentrations.
In general, the sample volume chamber in the CD determines the sensitivity of the assay. Many assays can be run using Gyrolab Bioaffy 200. If sensitivity is critical then Gyrolab Bioaffy 1000 is the CD of choice since it can process 1000 nl of sample. The porous particles included in Gyrolab Bioaffy 20 HC and Gyrolab 1000 HC CD allows for higher binding capacity. Gyrolab Bioaffy 20 HC is suitable when samples contain high analyte concentrations, such as in IgG in cell culture samples. Gyrolab Bioaffy 1000 HC has demonstrated improved performance when capture reagents displays low affinity binding to the analyte.
Gyrolab Mixing CD 96 integrates and automates sample pretreatment into the assay workflow made possible by Gyrolab platforms. Automating sample pretreatment and immunoassay workflow at nanoliter scale creates a number of advantages including:
In Gyrolab automated method for detection of leached MabSelect SuRe™ ligands, samples are acidified in Gyrolab Mixing CD 96 to dissociate protein A-IgG complexes. The amount of Protein A is then determined by a sandwich immunoassay.
For anti-drug antibody (ADA) analysis in preclinical or clinical serum samples, the mixing function in the Gyrolab Mixing CD 96 can be used to automate sample pre-treatment for acid dissociation of interfering biotherapeutic. Miniaturization simplifies detection of anti-drug antibodies, even in the presence of a high drug concentration. The individual microstructures integrate the acid dissociation process to minimize variation between samples, while edicated Gyrolab ADA software supports assay development and validation for cut point determination, screening and confirmatory analysis.
when used for ADA analysis.
Contact Gyros Protein Technologies for assistance with your assay development needs.
Pharmacokinetics/Toxicokinetics
“Better Science – fewer animals” Nanoliter-scale assays reduce animal usage in preclinical studies 
Pharmacodynamics & Biomarker Monitoring
Extract maximum biomarker/PD information from limited sample volumes
Immunogenicity
Automated sample pretreatment and immunoassay workflow at nanoliter-scale reduces hands-on time
Affinity
Design and evaluate in solution affinity runs using non-modified substances
Product Titer Quantitation
Broad dynamic range ensures high-sensitivity quantification throughout the development process
Impurities for downstream purification
Rapid quantification of contaminants enables data-driven decisions to be made throughout the biotherapeutics workflow
Get in touch
